TIBOLA : Multicenter Descriptive Study in Eastern France
NCT ID: NCT05458245
Last Updated: 2022-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2022-06-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Transmitted by ticks (Dermacentor), it is characterized by an inoculation eschar at the tick bite site, accompanied by painful loco-regional lymphadenopathy. It is most often a benign pathology, which can nevertheless leave sequellar alopecia or persistent asthenia.
In spring 2021, an impression of increased cases was reported by clinicians in Eastern France. The study aims to clarify the clinical-biological presentation and the evolution of the number of cases of TIBOLA in this region between 2016 and 2021.
At the same time, entomologists have noted an upsurge in this tick in certain biotopes in recent years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Anaplasmosis in Eastern France
NCT01013636
Tick-borne Encephalitis Virus Research in Limousin
NCT05941546
Analysis of Lyme Disease Lesions
NCT00132327
Borrelia Species in Cutaneous Lyme Borreliosis
NCT00576082
Risk of Exposure and Prevention of Ticks and Tick-borne Diseases Among Foresters in Alsace
NCT06492668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having been diagnosed with TIBOLA
* between January 1, 2016 and December 31, 2021
* at the University Hospital of Nancy or Strasbourg in the departments of infectious and tropical diseases, dermatology, microbiology and pediatrics.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elisabeth BAUX
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yves Hansmann
Strasbourg, , France
Elisabeth Baux
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kotzyba J, Baux E, Hansmann Y, Boyer P, Jaulhac B, Martinot M, Martha B, Kaeuffer C, Bonijoly T, Bani-Sadr F, Legoff A, Hoefler F, Blot M, Bourdellon L, Zilliox L, Boulanger N, Lefevre B. Tick-borne lymphadenopathy in northeastern France: a human and vector clinical-epidemiological study. Parasit Vectors. 2025 Oct 24;18(1):428. doi: 10.1186/s13071-025-07078-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021PI121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.